DXVX Recruits Lim Chang-gi, Peptide Expert from Hanmi

DXVX announced on the 24th that it has recruited Chang-ki Lim, a peptide expert, as the head of the New Drug Research Team 3 to strengthen new drug development.

Executive Director Lim previously worked at Hanmi Pharmaceutical's Bio Research Center and has held positions such as Director of Huons Group Bio Research Institute, Head of Biopharmaceutical Division at Anguk Pharmaceutical, and Head of R&D Strategy at Centrix Bio. He has extensive experience in various aspects of new drug development, including peptide and recombinant protein drug development, anticancer antibody drug development, bio-pharmaceutical efficacy evaluation, clinical trial applications (IND) for clinical entry, and license-out (technology transfer).

Given his experience leading peptide drug and anticancer agent development, it is expected that he will accelerate the development of OVM-200, an anticancer vaccine being developed in collaboration with the UK affiliate Oxford Vacmedix, and contribute to its early commercialization. Currently, DXVX is the largest shareholder of Oxford Vacmedix, holding 41% of its shares. OVM-200 is a recombinant overlapping peptide (ROP)-based anticancer vaccine that has completed Phase 1a clinical trials and is currently undergoing Phase 1b trials. Recently, a term sheet for license-in was agreed upon, and the main contract is about to be signed. DXVX plans to conduct late-stage clinical trials in Korea, China, and other Asian regions.

A DXVX representative stated, “With the recruitment of Executive Director Lim, a peptide development expert, we will upgrade the ROP technology in collaboration with Oxford Vacmedix and accelerate the development speed. We aim to promptly finalize the license-in main contract and promote early commercialization through rapid development programs such as full-scale late-stage clinical trials and accelerated approval.”

This content was produced with the assistance of AI translation services.